 Hanmant Gaikwad
Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nanoparticles | 7 | 2026 | 512 | 0.970 |
Why?
| | Complement Inactivating Agents | 2 | 2025 | 75 | 0.800 |
Why?
| | Integrins | 1 | 2023 | 90 | 0.750 |
Why?
| | Fibronectins | 1 | 2023 | 132 | 0.740 |
Why?
| | Click Chemistry | 4 | 2026 | 54 | 0.680 |
Why?
| | Complement C3 | 2 | 2023 | 192 | 0.630 |
Why?
| | Lipids | 3 | 2025 | 706 | 0.600 |
Why?
| | Lymphocytes | 1 | 2020 | 379 | 0.550 |
Why?
| | Monocytes | 1 | 2020 | 536 | 0.520 |
Why?
| | Polyethylene Glycols | 7 | 2026 | 653 | 0.490 |
Why?
| | Cell Membrane | 1 | 2019 | 706 | 0.450 |
Why?
| | Liposomes | 5 | 2025 | 256 | 0.430 |
Why?
| | Neutrophils | 1 | 2020 | 1118 | 0.420 |
Why?
| | Receptors, Complement 3d | 2 | 2026 | 142 | 0.410 |
Why?
| | Presbyopia | 2 | 2023 | 11 | 0.380 |
Why?
| | Doxorubicin | 3 | 2025 | 398 | 0.370 |
Why?
| | Lens, Crystalline | 2 | 2023 | 83 | 0.360 |
Why?
| | Nanomedicine | 2 | 2025 | 46 | 0.350 |
Why?
| | Fluorescent Dyes | 3 | 2022 | 333 | 0.330 |
Why?
| | Cathepsins | 2 | 2022 | 24 | 0.320 |
Why?
| | Immunoglobulin G | 3 | 2025 | 886 | 0.300 |
Why?
| | Antibodies | 2 | 2019 | 396 | 0.250 |
Why?
| | Recombinant Fusion Proteins | 2 | 2026 | 667 | 0.240 |
Why?
| | Rhodiola | 1 | 2025 | 1 | 0.220 |
Why?
| | Single-Domain Antibodies | 1 | 2025 | 15 | 0.220 |
Why?
| | Caspase 9 | 1 | 2025 | 51 | 0.220 |
Why?
| | Quinazolinones | 2 | 2015 | 19 | 0.220 |
Why?
| | Lipoproteins | 1 | 2025 | 165 | 0.210 |
Why?
| | Carbocyanines | 2 | 2025 | 37 | 0.210 |
Why?
| | Mice | 13 | 2025 | 18261 | 0.200 |
Why?
| | Plant Extracts | 1 | 2025 | 188 | 0.190 |
Why?
| | Pyrazoles | 3 | 2012 | 512 | 0.190 |
Why?
| | Complement System Proteins | 1 | 2026 | 314 | 0.190 |
Why?
| | Crystallins | 1 | 2023 | 29 | 0.190 |
Why?
| | Immunoglobulin M | 1 | 2024 | 281 | 0.190 |
Why?
| | Bone Neoplasms | 1 | 2025 | 255 | 0.180 |
Why?
| | Apoptosis | 2 | 2025 | 2397 | 0.180 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2024 | 835 | 0.180 |
Why?
| | Molecular Imaging | 1 | 2022 | 57 | 0.170 |
Why?
| | Ligands | 1 | 2023 | 662 | 0.170 |
Why?
| | Saccharomyces cerevisiae | 1 | 2025 | 579 | 0.160 |
Why?
| | Heterocyclic Compounds, 1-Ring | 1 | 2019 | 7 | 0.150 |
Why?
| | Cell-Derived Microparticles | 1 | 2020 | 72 | 0.150 |
Why?
| | Animals | 14 | 2025 | 37948 | 0.150 |
Why?
| | Collagen Type II | 1 | 2019 | 54 | 0.150 |
Why?
| | Jurkat Cells | 1 | 2019 | 114 | 0.150 |
Why?
| | Cathepsin L | 1 | 2019 | 9 | 0.150 |
Why?
| | Tandem Mass Spectrometry | 3 | 2023 | 565 | 0.150 |
Why?
| | Biological Transport | 1 | 2020 | 418 | 0.150 |
Why?
| | Color | 1 | 2019 | 81 | 0.140 |
Why?
| | Cathepsin B | 1 | 2019 | 16 | 0.140 |
Why?
| | Cyclooctanes | 1 | 2018 | 6 | 0.140 |
Why?
| | Piperazines | 2 | 2012 | 378 | 0.140 |
Why?
| | Bone Marrow | 1 | 2020 | 306 | 0.140 |
Why?
| | Glioblastoma | 1 | 2022 | 353 | 0.140 |
Why?
| | Complement Activation | 3 | 2026 | 409 | 0.130 |
Why?
| | Anti-Inflammatory Agents | 2 | 2019 | 477 | 0.130 |
Why?
| | Protein Binding | 1 | 2023 | 2243 | 0.120 |
Why?
| | Drug Delivery Systems | 1 | 2020 | 380 | 0.120 |
Why?
| | Glioma | 1 | 2021 | 429 | 0.120 |
Why?
| | Cell Line, Tumor | 5 | 2025 | 3523 | 0.110 |
Why?
| | Quinones | 1 | 2015 | 10 | 0.110 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2015 | 56 | 0.110 |
Why?
| | Carbazoles | 1 | 2015 | 54 | 0.110 |
Why?
| | Mice, Inbred BALB C | 3 | 2025 | 1251 | 0.110 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 2 | 2012 | 179 | 0.100 |
Why?
| | Drug Design | 1 | 2015 | 176 | 0.100 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 228 | 0.100 |
Why?
| | Pyrroles | 1 | 2015 | 213 | 0.100 |
Why?
| | Histone Deacetylases | 1 | 2015 | 207 | 0.100 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2015 | 218 | 0.100 |
Why?
| | Humans | 17 | 2026 | 144671 | 0.100 |
Why?
| | Erythrocytes | 1 | 2019 | 750 | 0.100 |
Why?
| | Brain Neoplasms | 1 | 2022 | 1327 | 0.090 |
Why?
| | Disulfides | 2 | 2023 | 94 | 0.090 |
Why?
| | Solubility | 2 | 2023 | 236 | 0.090 |
Why?
| | Breast Neoplasms | 1 | 2025 | 2365 | 0.090 |
Why?
| | Chromatography, Liquid | 2 | 2023 | 444 | 0.080 |
Why?
| | Macrophages | 1 | 2019 | 1496 | 0.080 |
Why?
| | T-Lymphocytes | 1 | 2019 | 1984 | 0.080 |
Why?
| | Amides | 1 | 2011 | 99 | 0.080 |
Why?
| | Carboxylic Acids | 1 | 2010 | 33 | 0.080 |
Why?
| | Imidazoles | 1 | 2012 | 246 | 0.080 |
Why?
| | Lipase | 1 | 2011 | 75 | 0.080 |
Why?
| | Arthritis, Rheumatoid | 1 | 2019 | 1170 | 0.080 |
Why?
| | Molecular Structure | 3 | 2018 | 495 | 0.080 |
Why?
| | Quinolines | 1 | 2011 | 192 | 0.080 |
Why?
| | Water | 2 | 2023 | 468 | 0.070 |
Why?
| | Flow Cytometry | 2 | 2025 | 1154 | 0.070 |
Why?
| | Rats | 3 | 2025 | 5570 | 0.070 |
Why?
| | Bone Marrow Cells | 2 | 2020 | 321 | 0.070 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 338 | 0.070 |
Why?
| | Ferric Compounds | 1 | 2025 | 54 | 0.050 |
Why?
| | Dogs | 1 | 2025 | 438 | 0.050 |
Why?
| | Receptors, Complement 3b | 1 | 2023 | 80 | 0.050 |
Why?
| | Down-Regulation | 1 | 2025 | 616 | 0.050 |
Why?
| | Acetylation | 1 | 2023 | 249 | 0.050 |
Why?
| | Dextrans | 1 | 2022 | 86 | 0.040 |
Why?
| | Structure-Activity Relationship | 2 | 2015 | 564 | 0.040 |
Why?
| | NIH 3T3 Cells | 1 | 2022 | 147 | 0.040 |
Why?
| | Endothelium | 1 | 2022 | 119 | 0.040 |
Why?
| | Lysine | 1 | 2023 | 271 | 0.040 |
Why?
| | Microscopy, Confocal | 1 | 2021 | 317 | 0.040 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2011 | 190 | 0.040 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2020 | 78 | 0.040 |
Why?
| | Phospholipids | 1 | 2021 | 214 | 0.040 |
Why?
| | Microscopy, Fluorescence | 1 | 2021 | 407 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2011 | 2201 | 0.040 |
Why?
| | RAW 264.7 Cells | 1 | 2019 | 48 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2015 | 2019 | 0.040 |
Why?
| | Mitochondrial Dynamics | 1 | 2019 | 40 | 0.030 |
Why?
| | Models, Molecular | 2 | 2015 | 1610 | 0.030 |
Why?
| | Drug Carriers | 1 | 2018 | 132 | 0.030 |
Why?
| | Arthritis, Experimental | 1 | 2019 | 141 | 0.030 |
Why?
| | Cartilage | 1 | 2019 | 198 | 0.030 |
Why?
| | Surface Properties | 1 | 2018 | 399 | 0.030 |
Why?
| | Particle Size | 1 | 2018 | 401 | 0.030 |
Why?
| | Cholesterol | 1 | 2019 | 404 | 0.030 |
Why?
| | Autophagy | 1 | 2019 | 284 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2019 | 601 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2019 | 743 | 0.030 |
Why?
| | Histone Deacetylase 2 | 1 | 2015 | 10 | 0.030 |
Why?
| | Female | 4 | 2025 | 78304 | 0.030 |
Why?
| | Histone Deacetylase 1 | 1 | 2015 | 23 | 0.030 |
Why?
| | Inhibitory Concentration 50 | 1 | 2015 | 90 | 0.030 |
Why?
| | K562 Cells | 1 | 2015 | 93 | 0.030 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 1 | 2015 | 55 | 0.030 |
Why?
| | MCF-7 Cells | 1 | 2015 | 132 | 0.030 |
Why?
| | Molecular Docking Simulation | 1 | 2015 | 121 | 0.030 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2015 | 79 | 0.030 |
Why?
| | HeLa Cells | 1 | 2015 | 632 | 0.020 |
Why?
| | Tumor Suppressor Proteins | 1 | 2015 | 319 | 0.020 |
Why?
| | Cellular Senescence | 1 | 2015 | 223 | 0.020 |
Why?
| | Aged | 2 | 2023 | 25955 | 0.020 |
Why?
| | Deuterium Exchange Measurement | 1 | 2012 | 27 | 0.020 |
Why?
| | Mitochondria | 1 | 2019 | 984 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2019 | 1338 | 0.020 |
Why?
| | Methanol | 1 | 2012 | 45 | 0.020 |
Why?
| | Cell Cycle | 1 | 2015 | 595 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2023 | 5967 | 0.020 |
Why?
| | Proteomics | 1 | 2019 | 1183 | 0.020 |
Why?
| | Cations | 1 | 2012 | 82 | 0.020 |
Why?
| | Carrageenan | 1 | 2011 | 8 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2019 | 3109 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2019 | 4110 | 0.020 |
Why?
| | Stereoisomerism | 1 | 2011 | 102 | 0.020 |
Why?
| | Candida | 1 | 2011 | 45 | 0.020 |
Why?
| | Biocatalysis | 1 | 2011 | 68 | 0.020 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2015 | 532 | 0.020 |
Why?
| | Spectroscopy, Fourier Transform Infrared | 1 | 2010 | 89 | 0.020 |
Why?
| | Edema | 1 | 2011 | 124 | 0.020 |
Why?
| | Male | 3 | 2024 | 72431 | 0.020 |
Why?
| | Neoplasms | 1 | 2024 | 2873 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4539 | 0.020 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2010 | 625 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2011 | 2489 | 0.010 |
Why?
| | Middle Aged | 1 | 2024 | 35971 | 0.010 |
Why?
| | Adult | 1 | 2024 | 40489 | 0.010 |
Why?
|
|
Gaikwad's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|